The role of T-helper cells in atherosclerosis

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2011, Pages 25-41

  Lu, X ^a   Lu, D ^b   Narayan, U ^c   Kakkar, V V ^a,c  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c THROMBOSIS RESEARCH INSTITUTE   (India)

Author keywords

Atherosclerosis; Cluster of differentiation; Cytokine; T regulation cells; T helper cell

Indexed keywords

CD28 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD81 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 27; INTERLEUKIN 31; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; STAT1 PROTEIN; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE COURSE; HELPER CELL; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; TH0 CELL; TH1 CELL; TH17 CELL; TH2 CELL; TH3 CELL;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; CYTOKINES; HUMANS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 79952729295     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152511794182819     Document Type: Article

References (288)

1. Hansson, G.K.; Libby, P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 2006, 6(7), 508-519.
2. Norata, G.D.; Marchesi, P.; Passamonti, S.; Pirillo, A.; Violi, F.; Catapano, A.L. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis, 2007, 191(2), 265-271.
3. Virella, G.; Lopes-Virella, M.F. Humoral immunity and atherosclerosis. Nat. Med., 2003, 9(3), 243-4; author reply 244-245.
4. Rose, N.; Afanasyeva, M. Autoimmunity: busting the atherosclerotic plaque. Nat. Med., 2003, 9(6), 641-642.
5. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352(16), 1685-1695.
6. Millonig, G.; Malcom, G.T.; Wick, G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Patho-biological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis, 2002, 160(2), 441-448.
7. Mai, G.; Bucher, P.; Morel, P.; Mei, J.; Bosco, D.; Andres, A.; Mathe, Z.; Wekerle, T.; Berney, T.; Buhler, L.H. Role of CD40-CD154 pathway in the rejection of concordant and discordant xenogeneic islets. Transplant. Proc., 2005, 37(1), 460-462.
8. Shashkin, P.; Dragulev, B.; Ley, K. Macrophage differentiation to foam cells. Curr. Pharm. Des., 2005, 11(23), 3061-3072.
9. van Boxel-Dezaire, A.H.; Stark, G.R. Cell type-specific signaling in response to interferon-gamma. Curr. Top. Microbiol. Immunol., 2007, 316, 119-154.
10. Kim, S.H.; Han, S.Y.; Azam, T.; Yoon, D.Y.; Dinarello, C.A. Inter-leukin-32: a cytokine and inducer of TNFalpha. Immunity, 2005, 22(1), 131-142.
11. Sommer, G.; Kralisch, S.; Stangl, V.; Vietzke, A.; Kohler, U.; Stepan, H.; Faber, R.; Schubert, A.; Lossner, U.; Bluher, M.; Stum-voll, M.; Fasshauer, M. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothe-lial cells. J. Cell. Biochem., 2009, 106(4), 729-737.
12. Hartman D. Genitourinary case of the day. Autosomal dominant polycystic kidney disease complicated by thoracic aortic dissection. AJR Am J Roentgenol., 1994; 162(6), 1454.
13. Jonasson, L.; Holm, J.; Skalli, O.; Bondjers, G.; Hansson, G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis, 1986, 6(2), 131-138.
14. Hansson, G.K.; Holm, J.; Jonasson, L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol., 1989, 135(1), 169-175.
15. Emeson, E.E.; Robertson, A.L., Jr. T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. Am. J. Pathol., 1988, 130(2), 369-376.
16. Reardon, C.A.; Blachowicz, L.; White, T.; Cabana, V.; Wang, Y.; Lukens, J.; Bluestone, J.; Getz, G.S. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21(6), 1011-1016.
17. Zhou, X.; Nicoletti, A.; Elhage, R.; Hansson, G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation, 2000, 102(24), 2919-2922.
18. Smith, E.; Prasad, K.M.; Butcher, M.; Dobrian, A.; Kolls, J.K.; Ley, K.; Galkina, E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2010, 121(15), 1746-1755.
19. de Boer, O.J.; Becker, A.E.; van der Wal, A.C. T lymphocytes in atherogenesis-functional aspects and antigenic repertoire. Cardio-vasc. Res., 2003, 60(1), 78-86.
20. George, J.; Harats, D.; Gilburd, B.; Afek, A.; Shaish, A.; Kopolovic, J.; Shoenfeld, Y. Adoptive transfer of beta-2-glycoprotein-I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation, 2000, 102(15), 1822-1827.
21. Dhawan, S.S.; Quyyumi, A.A. Rheumatoid arthritis and cardiovascular disease. Curr. Atheroscler. Rep., 2008, 10(2), 128-133.
22. Sato, H.; Miida, T.; Wada, Y.; Maruyama, M.; Murakami, S.; Hasegawa, H.; Kuroda, T.; Narita, I.; Nakano, M.; Gejyo, F. Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin. Chim. Acta, 2007, 385(1-2), 35-42.
23. Jara, L.J.; Medina, G.; Vera-Lastra, O. Systemic antiphospholipid syndrome and atherosclerosis. Clin. Rev. Allergy Immunol., 2007, 32(2), 172-177.
24. Zhou, X.; Hansson, G.K. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand. J. Immunol., 1999, 50(1), 25-30.
25. Kaartinen, M.; Penttila, A.; Kovanen, P.T. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation, 1996, 94(11), 2787-2792.
26. Bradding, P. Human mast cell cytokines. Clin. Exp. Allergy, 1996, 26(1), 13-19.
27. Johnson, J.L.; Jackson, C.L.; Angelini, G.D.; George, S.J. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol., 1998, 18(11), 1707-1715.
28. Fourcade, J.; Sun, Z.; Kudela, P.; Janjic, B.; Kirkwood, J.M.; El-Hafnawy, T.; Zarour, H.M. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J. Immunol., 2010, 184(12), 6709-6718.
29. Choi, J.H.; Do, Y.; Cheong, C.; Koh, H.; Boscardin, S.B.; Oh, Y.S.; Bozzacco, L.; Trumpfheller, C.; Park, C.G.; Steinman, R.M. Identi-fication of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J. Exp. Med., 2009, 206(3), 497-505.
30. Paulson, K.E.; Zhu, S.N.; Chen, M.; Nurmohamed, S.; Jongstra-Bilen, J.; Cybulsky, M.I. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res., 2010, 106(2), 383-390.
31. Sun, J.; Sukhova, G.K.; Wolters, P.J.; Yang, M.; Kitamoto, S.; Libby, P.; MacFarlane, L.A.; Mallen-St Clair, J.; Shi, G.P. Mast cells promote atherosclerosis by releasing proinflammatory cytoki-nes. Nat. Med., 2007, 13(6), 719-724.
32. Gajewski, T.F.; Lancki, D.W.; Stack, R.; Fitch, F.W. Anergy of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J. Exp. Med., 1994, 179(2), 481-491.
33. Yamamoto, K.; Quelle, F. W.; Thierfelder, W. E.; Kreider, B. L.; Gilbert, D. J.; Jenkins, N. A.; Copeland, N. G.; Silvennoinen, O.; Ihle, J. N. Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. Mol. Cell. Biol., 1994, 14(7), 4342-4349.
34. Mullen, A.C.; High, F.A.; Hutchins, A.S.; Lee, H.W.; Villarino, A.V.; Livingston, D.M.; Kung, A.L.; Cereb, N.; Yao, T.P.; Yang, S.Y.; Reiner, S.L. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science, 2001, 292(5523), 1907-1910.
35. Afkarian, M.; Sedy, J.R.; Yang, J.; Jacobson, N.G.; Cereb, N.; Yang, S.Y.; Murphy, T.L.; Murphy, K.M. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat. Immunol., 2002, 3(6), 549-557.
36. Lighvani, A.A.; Frucht, D.M.; Jankovic, D.; Yamane, H.; Aliberti, J.; Hissong, B.D.; Nguyen, B.V.; Gadina, M.; Sher, A.; Paul, W.E.; O'Shea, J.J. T-bet is rapidly induced by interferon-gamma in lym-phoid and myeloid cells. Proc. Natl. Acad. Sci. USA, 2001, 98(26), 15137-15142.
37. Mamane, Y.; Sharma, S.; Grandvaux, N.; Hernandez, E.; Hiscott, J. IRF-4 activities in HTLV-I-induced T cell leukemogenesis. J. Interferon Cytokine Res., 2002, 22(1), 135-143.
38. Rust, K.; Grosso, L.; Zhang, V.; Chang, D.; Persson, A.; Longmore, W.; Cai, G.Z.; Crouch, E. Human surfactant protein D: SP-D contains a C-type lectin carbohydrate recognition domain. Arch. Biochem. Biophys., 1991, 290(1), 116-126.
39. Jakobsen, L.P.; Borup, R.; Vestergaard, J.; Larsen, L.A.; Lage, K.; Maroun, L.L.; Kjaer, I.; Niemann, C.U.; Andersen, M.; Knudsen, M.A.; Mollgard, K.; Tommerup, N. Expression analyses of human cleft palate tissue suggest a role for osteopontin and immune related factors in palatal development. Exp. Mol. Med., 2009, 41(2), 77-85.
40. Cantor, H.; Shinohara, M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol., 2009, 9(2), 137-141.
41. Mosmann, T.R.; Cherwinski, H.; Bond, M.W.; Giedlin, M.A.; Coffman, R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., 1986, 136(7), 2348-2357.
42. Niessner, A.; Steiner, S.; Speidl, W. S.; Pleiner, J.; Seidinger, D.; Maurer, G.; Goronzy, J.J.; Weyand, C.M.; Kopp, C.W.; Huber, K.; Wolzt, M.; Wojta, J. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis, 2006, 189(2), 408-413.
43. Cheng, X.; Ding, Y.; Xia, C.; Tang, T.; Yu, X.; Xie, J.; Liao, M.; Yao, R.; Chen, Y.; Wang, M.; Liao, Y.H. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J. Card. Fail., 2009, 15(2), 158-162.
44. Kubo, T.; Hatton, R.D.; Oliver, J.; Liu, X.; Elson, C.O.; Weaver, C.T. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J. Immunol., 2004,173(12), 7249-7258.
45. Galea, J.; Armstrong, J.; Gadsdon, P.; Holden, H.; Francis, S. E.; Holt, C.M. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol., 1996, 16(8), 1000-1006.
46. Chizzolini, C.; Chicheportiche, R.; Burger, D.; Dayer, J. M. Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur. J. Immunol., 1997, 27(1), 171-177.
47. Bocker, U.; Damiao, A.; Holt, L.; Han, D.S.; Jobin, C.; Panja, A.; Mayer, L.; Sartor, R. B. Differential expression of interleukin 1 receptor antagonist isoforms in human intestinal epithelial cells. Gastroenterology, 1998, 115(6), 1426-1438.
48. Chamberlain, J.; Francis, S.; Brookes, Z.; Shaw, G.; Graham, D.; Alp, N.J.; Dower, S.; Crossman, D.C. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One, 2009, 4, e50734.
49. Elhage, R.; Maret, A.; Pieraggi, M.T.; Thiers, J.C.; Arnal, J.F.; Bayard, F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation, 1998, 97(3), 242-244.
50. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nunez, G.; Schnurr, M.; Espevik, T.; Lien, E.; Fitzgerald, K.A.; Rock, K.L.; Moore, K.J.; Wright, S.D.; Hornung, V.; Latz, E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 2010, 464(7293), 1357-1361.
51. Devlin, C.M.; Kuriakose, G.; Hirsch, E.; Tabas, I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc. Natl. Acad. Sci. USA, 2002, 99(9), 6280-6285.
52. Clarke, M.C.; Talib, S.; Figg, N.L.; Bennett, M.R. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ. Res., 2010, 106(2), 363-372.
53. Crossman, D.C.; Morton, A.C.; Gunn, J.P.; Greenwood, J.P.; Hall, A.S.; Fox, K.A.; Lucking, A.J.; Flather, M.D.; Lees, B.; Foley, C.E. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials, 2008, 9, 8.
54. Merhi-Soussi, F.; Kwak, B.R.; Magne, D.; Chadjichristos, C.; Berti, M.; Pelli, G.; James, R.W.; Mach, F.; Gabay, C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res., 2005, 66(3), 583-593.
55. Isoda, K.; Sawada, S.; Ishigami, N.; Matsuki, T.; Miyazaki, K.; Kusuhara, M.; Iwakura, Y.; Ohsuzu, F. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2004, 24(6), 1068-1073.
56. Isoda, K.; Ohsuzu, F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J. Atheroscler. Thromb., 2006, 13(1), 21-30.
57. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2003, 23(4), 656-660.
58. Kamari, Y.; Werman-Venkert, R.; Shaish, A.; Werman, A.; Harari, A.; Gonen, A.; Voronov, E.; Grosskopf, I.; Sharabi, Y.; Grossman, E.; Iwakura, Y.; Dinarello, C.A.; Apte, R.N.; Harats, D. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis, 2007, 195(1), 31-38.
59. Chi, H.; Messas, E.; Levine, R.A.; Graves, D.T.; Amar, S. Interleu-kin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation, 2004, 110(12), 1678-1685.
60. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol., 2003, 3(2), 133-146.
61. Oviedo-Orta, E.; Bermudez-Fajardo, A.; Karanam, S.; Benbow, U.; Newby, A.C. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology, 2008, 124(1), 42-50.
62. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell Biol., 2007, 8(3), 221-233.
63. Newby, A.C. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr. Opin. Lipidol., 2006, 17(5), 556-561.
64. Melter, M.; Exeni, A.; Reinders, M.E.; Fang, J.C.; McMahon, G.; Ganz, P.; Hancock, W.W.; Briscoe, D.M. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation, 2001, 104(21), 2558-2564.
65. Fraticelli, P.; Sironi, M.; Bianchi, G.; D'Ambrosio, D.; Albanesi, C.; Stoppacciaro, A.; Chieppa, M.; Allavena, P.; Ruco, L.; Girolo-moni, G.; Sinigaglia, F.; Vecchi, A.; Mantovani, A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest., 2001, 107(9), 1173-1181.
66. Burns, W.R.; Wang, Y.; Tang, P.C.; Ranjbaran, H.; Iakimov, A.; Kim, J.; Cuffy, M.; Bai, Y.; Pober, J.S.; Tellides, G. Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma-inducible chemokines in rejecting human arteries. Am. J. Transplant., 2005, 5(6), 1226-1236.
67. Loetscher, M.; Gerber, B.; Loetscher, P.; Jones, S.A.; Piali, L.; Clark-Lewis, I.; Baggiolini, M.; Moser, B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med., 1996, 184(3), 963-969.
68. Sallusto, F.; Lanzavecchia, A.; Mackay, C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today, 1998, 19(12), 568-574.
69. Bonecchi, R.; Bianchi, G.; Bordignon, P.P.; D'Ambrosio, D.; Lang, R.; Borsatti, A.; Sozzani, S.; Allavena, P.; Gray, P.A.; Mantovani, A.; Sinigaglia, F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med., 1998, 187(1), 129-134.
70. Loetscher, P.; Uguccioni, M.; Bordoli, L.; Baggiolini, M.; Moser, B.; Chizzolini, C.; Dayer, J.M. CCR5 is characteristic of Th1 lymphocytes. Nature, 1998, 391(6665), 344-345.
71. Bach, E.A.; Aguet, M.; Schreiber, R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol., 1997,15, 563-591.
72. Harris, D.P.; Haynes, L.; Sayles, P.C.; Duso, D.K.; Eaton, S.M.; Lepak, N.M.; Johnson, L.L.; Swain, S.L.; Lund, F.E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol., 2000, 1(6), 475-482.
73. Tellides, G.; Pober, J.S. Interferon-gamma axis in graft arteriosclerosis. Circ. Res., 2007, 100(5), 622-632.
74. Paludan, S.R. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol., 1998, 48(5), 459-468.
75. Heinzel, F.P.; Rerko, R.M.; Ahmed, F.; Hujer, A.M. IFN-gamma-independent production of IL-12 during murine endotoxemia. J. Immunol., 1996, 157(10), 4521-4528.
76. Ghadimi, D.; de Vrese, M.; Heller, K.J.; Schrezenmeir, J. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacte-rium tuberculosis antigen. Int. Immunopharmacol., 2010, 10(6), 694-706.
77. Boehm, U.; Klamp, T.; Groot, M.; Howard, J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol., 1997, 15, 749-795.
78. Foulds, K.E.; Rotte, M.J.; Paley, M.A.; Singh, B.; Douek, D.C.; Hill, B.J.; O'Shea, J.J.; Watford, W.T.; Seder, R.A.; Wu, C.Y. IFN-gamma mediates the death of Th1 cells in a paracrine manner. J. Immunol., 2008, 180(2), 842-849.
79. Stemme, S.; Faber, B.; Holm, J.; Wiklund, O.; Witztum, J.L.; Hansson, G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA, 1995, 92(9), 3893-3897.
80. Buono, C.; Come, C.E.; Stavrakis, G.; Maguire, G.F.; Connelly, P.W.; Lichtman, A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol., 2003, 23(3), 454-460.
81. Whitman, S.C.; Ravisankar, P.; Daugherty, A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipo-protein E-/-mice. J. Interferon Cytokine Res., 2002, 22(6), 661-670.
82. Whitman, S.C.; Ravisankar, P.; Elam, H.; Daugherty, A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/-mice. Am. J. Pathol., 2000, 157(6), 1819-1824.
83. Charnaux, N.; Brule, S.; Chaigneau, T.; Saffar, L.; Sutton, A.; Hamon, M.; Prost, C.; Lievre, N.; Vita, C.; Gattegno, L. RANTES (CCL5) induces a CCR5-dependent accelerated shedding of synde-can-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology, 2005, 15(2), 119-130.
84. Pattison, J.M.; Nelson, P.J.; Huie, P.; Sibley, R.K.; Krensky, A.M. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant., 1996, 15(12), 1194-1199.
85. Kao, J.; Kobashigawa, J.; Fishbein, M.C.; MacLellan, W.R.; Burdick, M.D.; Belperio, J.A.; Strieter, R.M. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation, 2003, 107(15), 1958-1961.
86. Hansson, G.K.; Hellstrand, M.; Rymo, L.; Rubbia, L.; Gabbiani, G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med., 1989, 170(5), 1595-1608.
87. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105(9), 1135-1143.
88. Hansson, G.K. Immune mechanisms in atherosclerosis. Arterio-scler. Thromb. Vasc. Biol., 2001, 21(12), 1876-1890.
89. Gupta, S.; Pablo, A.M.; Jiang, X.; Wang, N.; Tall, A.R.; Schindler, C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest., 1997, 99(11), 2752-2761.
90. Ayada, K.; Yokota, K.; Kobayashi, K.; Shoenfeld, Y.; Matsuura, E.; Oguma, K. Chronic infections and atherosclerosis. Clin. Rev. Allergy Immunol., 2009, 37(1), 44-48.
91. Aukrust, P.; Otterdal, K.; Yndestad, A.; Sandberg, W.J.; Smith, C.; Ueland, T.; Oie, E.; Damas, J.K.; Gullestad, L.; Halvorsen, B. The complex role of T-cell-based immunity in atherosclerosis. Curr. Atheroscler. Rep., 2008, 10(3), 236-243.
92. Ben-Shoshan, J.; Afek, A.; Maysel-Auslender, S.; Barzelay, A.; Rubinstein, A.; Keren, G.; George, J. HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2009, 29(5), 665-670.
93. Laurat, E.; Poirier, B.; Tupin, E.; Caligiuri, G.; Hansson, G.K.; Bariety, J.; Nicoletti, A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation, 2001, 104(2), 197-202.
94. Mallat, Z.; Corbaz, A.; Scoazec, A.; Graber, P.; Alouani, S.; Espo-sito, B.; Humbert, Y.; Chvatchko, Y.; Tedgui, A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res., 2001, 89, E41-E57.
95. Whitman, S.C.; Ravisankar, P.; Daugherty, A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res., 2002, 90, E34-E82.
96. Shah, P.K. Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol., 2003, 41(4 suppl.), 15S-22S.
97. Mallat, Z.; Hugel, B.; Ohan, J.; Leseche, G.; Freyssinet, J.M.; Ted-gui, A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation, 1999, 99(3), 348-353.
98. Fernandez-Ortiz, A.; Badimon, J.J.; Falk, E.; Fuster, V.; Meyer, B.; Mailhac, A.; Weng, D.; Shah, P.K.; Badimon, L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J. Am. Coll. Cardiol., 1994, 23(7), 1562-1569.
99. Li, H.; Cybulsky, M.I.; Gimbrone, M.A., Jr; Libby, P. An athero-genic diet rapidly induces VCAM-1, a cytokine-regulatable mono-nuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb., 1993, 13(2), 197-204.
100. Jonasson, L.; Holm, J.; Skalli, O.; Gabbiani, G.; Hansson, G.K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest., 1985, 76(1), 125-131.
101. Zuckerman, S.H.; Panousis, C.; Mizrahi, J.; Evans, G. The effect of gamma-interferon to inhibit macrophage-high density lipoprotein interactions is reversed by 15-deoxy-delta12,14-prostaglandin J2. Lipids, 2000, 35(11), 1239-1247.
102. Li, H.; Freeman, M.W.; Libby, P. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J. Clin. Invest., 1995, 95(1), 122-133.
103. Geng, Y.J.; Hansson, G.K. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J. Clin. Invest., 1992, 89(4), 1322-1330.
104. Nickel, T.; Schmauss, D.; Hanssen, H.; Sicic, Z.; Krebs, B.; Jankl, S.; Summo, C.; Fraunberger, P.; Walli, A.K.; Pfeiler, S.; Weis, M. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis, 2009, 205(2), 442-450.
105. Li, X.; Syrovets, T.; Genze, F.; Pitterle, K.; Oberhuber, A.; Orend, K.H.; Simmet, T. Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response. Arterioscler. Thromb. Vasc. Biol., 2010, 30(3), 582-590.
106. Panousis, C.G.; Zuckerman, S.H. Regulation of cholesterol distribution in macrophage-derived foam cells by interferon-gamma. J. Lipid Res., 2000, 41(1), 75-83.
107. Brand, K.; Mackman, N.; Curtiss, L.K. Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J. Clin. Invest., 1993, 91, 2031-2039.
108. Panousis, C.G.; Zuckerman, S.H. Interferon-gamma induces down-regulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler. Thromb. Vasc. Biol., 2000, 20(6), 1565-1571.
109. Albrecht, C.; Soumian, S.; Amey, J.S.; Sardini, A.; Higgins, C.F.; Davies, A.H.; Gibbs, R.G. ABCA1 expression in carotid atherosclerotic plaques. Stroke, 2004, 35(12), 2801-2806.
110. Lusis, A.J. Atherosclerosis. Nature, 2000, 407(6801), 233-241.
111. Lusis, A.J.; Mar, R.; Pajukanta, P. Genetics of atherosclerosis. Annu. Rev. Genomics Hum. Genet., 2004, 5, 189-218.
112. Inagaki, Y.; Yamagishi, S.; Amano, S.; Okamoto, T.; Koga, K.; Makita, Z. Interferon-gamma-induced apoptosis and activation of THP-1 macrophages. Life Sci., 2002, 71(21), 2499-2508.
113. Rosner, D.; Stoneman, V.; Littlewood, T.; McCarthy, N.; Figg, N.; Wang, Y.; Tellides, G.; Bennett, M. Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K-and Akt-dependent mechanism. Am. J. Pathol., 2006, 168(6), 2054-2063.
114. Babaev, V.R.; Fazio, S.; Gleaves, L.A.; Carter, K.J.; Semenkovich, C.F.; Linton, M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest., 1999, 103(12), 1697-1705.
115. Fong, L.G.; Albert, T.S.; Hom, S.E. Inhibition of the macrophage-induced oxidation of low density lipoprotein by interferon-gamma. J. Lipid Res., 1994, 35(5), 893-904.
116. Hughes, T.R.; Tengku-Muhammad, T.S.; Irvine, S.A.; Ramji, D.P. A novel role of Sp1 and Sp3 in the interferon-gamma-mediated suppression of macrophage lipoprotein lipase gene transcription. J. Biol. Chem., 2002, 277(13), 11097-1106.
117. Yokoyama, M.; Hirata, K.; Kawashima, S.; Kawahara, Y. Regulation of nitric oxide synthase gene expression by cytokines. J. Card. Fail., 1996, 2(4 Suppl.), S179-S185.
118. Huo, Y.; Zhao, L.; Hyman, M.C.; Shashkin, P.; Harry, B.L.; Burcin, T.; Forlow, S.B.; Stark, M. A.; Smith, D.F.; Clarke, S.; Srinivasan, S.; Hedrick, C.C.; Pratico, D.; Witztum, J.L.; Nadler, J.L.; Funk, C.D.; Ley, K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004, 110(14), 2024-2031.
119. Morrow, M.P.; Pankhong, P.; Laddy, D.J.; Schoenly, K.A.; Yan, J.; Cisper, N.; Weiner, D.B. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood, 2009, 113(23), 5868-5877.
120. Murphy, K.M.; Ouyang, W.; Farrar, J.D.; Yang, J.; Ranganath, S.; Asnagli, H.; Afkarian, M.; Murphy, T.L. Signaling and transcription in T helper development. Annu. Rev. Immunol., 2000, 18, 451-494.
121. Davenport, P.; Tipping, P.G. The role of interleukin-4 and interleu-kin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol., 2003, 163(3), 1117-1125.
122. Shimozato, O.; Ugai, S.; Chiyo, M.; Takenobu, H.; Nagakawa, H.; Wada, A.; Kawamura, K.; Yamamoto, H.; Tagawa, M. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology, 2006, 117(1), 22-28.
123. Uyemura, K.; Demer, L.L.; Castle, S.C.; Jullien, D.; Berliner, J.A.; Gately, M.K.; Warrier, R.R.; Pham, N.; Fogelman, A.M.; Modlin, R.L. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest., 1996, 97(9), 2130-2138.
124. Lee, T.S.; Yen, H.C.; Pan, C.C.; Chau, L.Y. The role of interleu-kin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol., 1999, 19(3), 734-742.
125. Lienenluke, B.; Germann, T.; Kroczek, R.A.; Hecker, M. CD154 stimulation of interleukin-12 synthesis in human endothelial cells. Eur. J. Immunol., 2000, 30(10), 2864-2870.
126. Mason, N.; Aliberti, J.; Caamano, J.C.; Liou, H.C.; Hunter, C.A. Cutting edge: identification of c-Rel-dependent and-independent pathways of IL-12 production during infectious and inflammatory stimuli. J. Immunol., 2002, 168(6), 2590-2594.
127. Stokes, K.Y.; Clanton, E.C.; Gehrig, J.L.; Granger, D.N. Role of interleukin 12 in hypercholesterolemia-induced inflammation. Am. J. Physiol. Heart. Circ. Physiol., 2003, 285(6), H2623-H2629.
128. Bastos, K.R.; Marinho, C.R.; Barboza, R.; Russo, M.; Alvarez, J.M.; D'Império Lima, M.R. What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells? Microbes Infect., 2004, 6(6), 630-636.
129. Gao, D.; Mondal, T.K.; Lawrence, D.A. Lead effects on development and function of bone marrow-derived dendritic cells promote Th2 immune responses. Toxicol. Appl. Pharmacol., 2007, 222(1), 69-79.
130. Zhang, X.; Niessner, A.; Nakajima, T.; Ma-Krupa, W.; Kopecky, S.L.; Frye, R.L.; Goronzy, J.J.; Weyand, C.M. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ. Res., 2006, 9(4), 524-531.
131. Mosmann, T.R.; Coffman, R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 1989, 7, 145-173.
132. Janeway, C.A., Jr; Carding, S.; Jones, B.; Murray, J.; Portoles, P.; Rasmussen, R.; Rojo, J.; Saizawa, K.; West, J.; Bottomly, K. CD4+ T cells: specificity and function. Immunol. Rev., 1988, 101, 39-80.
133. Yawalkar, N.; Hunger, R. E.; Pichler, W.J.; Braathen, L.R.; Brand, C.U. Human afferent lymph from normal skin contains an increased number of mainly memory/effector CD4(+) T cells expressing activation, adhesion and co-stimulatory molecules. Eur. J. Immunol., 2000, 30(2), 491-497.
134. Boonacker, E.P.; Wierenga, E.A.; Smits, H.H.; Van Noorden, C.J. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J. Histo-chem. Cytochem., 2002, 50(9), 1169-1177.
135. Chang, C.; Rodriguez, A.; Carretero, M.; Lopez-Botet, M.; Phillips, J.H.; Lanier, L.L. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin super-family. Eur. J. Immunol., 1995, 25(9), 2433-2437.
136. Meyers, J.H.; Ryu, A.; Monney, L.; Nguyen, K.; Greenfield, E.A.; Freeman, G.J.; Kuchroo, V.K. Cutting edge: CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions. J. Immunol., 2002, 169(10), 5382-5386.
137. Lynch, E.A.; Heijens, C.A.; Horst, N.F.; Center, D.M.; Cruikshank, W.W. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J. Immunol., 2003, 171(10), 4965-4968.
138. Watanabe, M.; Yamamoto, N.; Maruoka, H.; Matsuzuka, F.; Miyauchi, A.; Iwatani, Y. Relation of CD30 molecules on T-cell subsets to the severity of autoimmune thyroid disease. Thyroid, 2003, 13(3), 259-263.
139. Houtkamp, M.A.; van Der Wal, A.C.; de Boer, O.J.; van Der Loos, C.M.; de Boer, P.A.; Moorman, A.F.; Becker, A.E. Interleukin-15 expression in atherosclerotic plaques: an alternative pathway for T-cell activation in atherosclerosis? Arterioscler. Thromb. Vasc. Biol., 2001, 21(7), 1208-1213.
140. Sareneva, T.; Julkunen, I.; Matikainen, S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J. Immunol., 2000, 165(4), 1933-1938.
141. Kaser, A.; Kaser, S.; Kaneider, N.C.; Enrich, B.; Wiedermann, C.J.; Tilg, H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood, 2004, 103(2), 648-655.
142. Aggarwal, S.; Ghilardi, N.; Xie, M.H.; de Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278(3), 1910-1914.
143. Ha, S.J.; Kim, D.J.; Baek, K.H.; Yun, Y.D.; Sung, Y.C. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J. Immunol., 2004, 172(1), 525-531.
144. Kempe, S.; Heinz, P.; Kokai, E.; Devergne, O.; Marx, N.; Wirth, T. Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques. Am. J. Pathol., 2009, 175(1), 440-447.
145. Owaki, T.; Asakawa, M.; Fukai, F.; Mizuguchi, J.; Yoshimoto, T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol., 2006, 177(11), 7579-7587.
146. Mayer, K.D.; Mohrs, K.; Reiley, W.; Wittmer, S.; Kohlmeier, J.E.; Pearl, J.E.; Cooper, A.M.; Johnson, L.L.; Woodland, D.L.; Mohrs, M. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-gamma production by CD8 T cells during infection. J. Immunol., 2008, 180(2), 693-697.
147. Beloqui, O.; Páramo, J.A.; Orbe, J.; Benito, A.; Colina, I.; Monas-terio, A.; Díez, J. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? Eur. Heart J., 2005, 26(2), 153-158.
148. Bozza, S.; Clavaud, C.; Giovannini, G. Immune Sensing of Asper-gillus fumigatus Proteins, Glycolipids, and Polysaccharides and the Impact on Th Immunity and Vaccination. J. Immunol., 2009, 183(4), 2407-2414.
149. Abbas, A.K.; Murphy, K.M.; Sher, A. Functional diversity of helper T lymphocytes. Nature, 1996, 383(6603), 787-793.
150. Sad, S.; Marcotte, R.; Mosmann, T.R. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity, 1995, 2(3), 271-279.
151. Finkelman, F.D.; Hogan, S.P.; Hershey, G.K.; Rothenberg, M.E.; Wills-Karp, M. Importance of cytokines in murine allergic airway disease and human asthma. J. Immunol., 2010, 184(4), 1663-1674.
152. Wu, Z.; Pearson, A.; Oliveira, D. Characterization of cis-regulatory elements conferring mercury-induced interleukin-4 gene expression in rat mast cells: a role for signal transducer and activator of transcription 6 and TATA box binding sites. Immunology, 2009, 127(4), 530-538.
153. Ryan, J.J.; Kashyap, M.; Bailey, D.; Kennedy, S.; Speiran, K.; Brenzovich, J.; Barnstein, B.; Oskeritzian, C.; Gomez, G. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit. Rev. Immunol., 2007, 27(1), 15-32.
154. Ensminger, S.M.; Spriewald, B.M.; Sorensen, H.V.; Witzke, O.; Flashman, E.G.; Bushell, A.; Morris, P.J.; Rose, M.L.; Rahemtulla, A.; Wood, K.J. Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of CD40-CD154 costimulation. J. Immunol., 2001, 167(1), 532-541.
155. Varin, A.; Mukhopadhyay, S.; Herbein, G.; Gordon, S. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood, 2010, 115(2), 353-362.
156. Fiset, P.O.; Tulic, M.K.; Skrablin, P.S.; Grover, S.M.; Létuvé, S.; Mazer, B.D.; Hamid, Q. Signal transducer and activator of transcription 6 down-regulates toll-like receptor-4 expression of a monocytic cell line. Clin. Exp. Allergy, 2006, 36(2), 158-165.
157. Ishikado, A.; Nishio, Y.; Yamane, K.; Mukose, A.; Morino, K.; Murakami, Y.; Sekine, O.; Makino, T.; Maegawa, H.; Kashiwagi, A. Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells. Atherosclerosis, 2009, 205(2), 404-412.
158. de Winther, M.P.; Kanters, E.; Kraal, G.; Hofker, M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2005, 25(5), 904-914.
159. Fitzgerald, K.A.; Palsson-McDermott, E.M.; Bowie, A.G.; Jeffer-ies, C.A.; Mansell, A.S.; Brady, G.; Brint, E.; Dunne, A.; Gray, P.; Harte, M.T.; McMurray, D.; Smith, D.E.; Sims, J.E.; Bird, T. A.; O'Neill, L.A. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature, 2001, 413(6851), 78-83.
160. Kanters, E.; Pasparakis, M.; Gijbels, M. J.; Vergouwe, M.N.; Partouns-Hendriks, I.; Fijneman, R. J.; Clausen, B.E.; Forster, I.; Kockx, M.M.; Rajewsky, K.; Kraal, G.; Hofker, M.H.; de Winther, M.P. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest., 2003, 112(8), 1176-1185.
161. Schonbeck, U.; Sukhova, G.K.; Gerdes, N.; Libby, P. T(H)2 predominant immune responses prevail in human abdominal aortic an-eurysm. Am. J. Pathol., 2002, 161(2), 499-506.
162. Kuhn, R.; Rajewsky, K.; Muller, W. Generation and analysis of interleukin-4 deficient mice. Science, 1991, 254(5032), 707-710.
163. Coffman, R.L.; Seymour, B.W.; Lebman, D.A.; Hiraki, D.D.; Christiansen, J.A.; Shrader, B.; Cherwinski, H.M.; Savelkoul, H.F.; Finkelman, F.D.; Bond, M.W. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev., 1988, 102, 5-28.
164. [164] Kawakami, T.; Kitaura, J.; Xiao, W.; Kawakami, Y. IgE regulation of mast cell survival and function. Novartis Found. Symp., 2005, 271, 100-7; discussion 108-14, 145-151.
165. Yamashita, M.; Kimura, M.; Kubo, M.; Shimizu, C.; Tada, T.; Perlmutter, R. M.; Nakayama, T. T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc. Natl. Acad. Sci. USA, 1999, 96(3), 1024-109.
166. Feng, J.; Han, J.; Pearce, S.F.; Silverstein, R.L.; Gotto, A.M.,Jr; Hajjar, D.P.; Nicholson, A.C. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J. Lipid Res., 2000, 41(5), 688-696.
167. Helming, L.; Winter, J.; Gordon, S. The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion. J. Cell. Sci., 2009, 122(pt4), 453-459.
168. Lee, Y.W.; Kuhn, H.; Hennig, B.; Neish, A.S.; Toborek, M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J. Mol. Cell. Cardiol., 2001, 33(1), 83-94.
169. Bergese, S.; Pelletier, R.; Vallera, D.; Widmer, M.; Orosz, C. Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Roles for TNF and IL4 Am. J. Pathol., 1995, 146(4), 989-998.
170. Pfistershammer, K.; Klauser, C.; Leitner, J.; Stockl, J.; Majdic, O.; Weichhart, T.; Sobanov, Y.; Bochkov, V.; Saemann, M.; Zlabinger, G.; Steinberger, P. Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. J. Leukoc. Biol., 2008, 83(1), 131-138.
171. Walch, L.; Massade, L.; Dufilho, M.; Brunet, A.; Rendu, F. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant pro-tein-1 expression. Atherosclerosis, 2006, 187(2), 285-291.
172. Conrad, D. J.; Kuhn, H.; Mulkins, M.; Highland, E.; Sigal, E. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl. Acad. Sci. USA, 1992, 89(1), 217-221.
173. Poeckel, D.; Zemski Berry, K.A.; Murphy, R.C.; Funk, C.D. Dual 12/15-and 5-lipoxygenase deficiency in macrophages alters ara-chidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice. J. Biol. Chem., 2009, 284(31), 21077-21089.
174. Reddy, M.A.; Sahar, S.; Villeneuve, L.M.; Lanting, L.; Natarajan, R. Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2009, 29(3), 387-393.
175. Febbraio, M.; Hajjar, D.P.; Silverstein, R.L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest., 2001, 108(6), 785-791.
176. Kunjathoor, V.V.; Febbraio, M.; Podrez, E.A.; Moore, K.J.; Andersson, L.; Koehn, S.; Rhee, J.S.; Silverstein, R.; Hoff, H.F.; Freeman, M.W. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem., 2002, 277(51), 49982-49988.
177. Cybulsky, M.I.; Gimbrone, M.A., Jr Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science, 1991, 251(4995), 788-791.
178. Nakashima, Y.; Raines, E.W.; Plump, A.S.; Breslow, J.L.; Ross, R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol., 1998, 18(5), 842-851.
179. O'Brien, K.D.; Allen, M.D.; McDonald, T.O.; Chait, A.; Harlan, J.M.; Fishbein, D.; McCarty, J.; Ferguson, M.; Hudkins, K.; Benjamin, C.D. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J. Clin. Invest., 1993, 92(2), 945-951.
180. Papadopoulou, C.; Corrigall, V.; Taylor, P.R.; Poston, R.N. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine, 2008, 43(2), 181-186.
181. Zhou, X.; Paulsson, G.; Stemme, S.; Hansson, G.K. Hypercholes-terolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest., 1998, 101(8), 1717-1725.
182. King, V.L.; Szilvassy, S.J.; Daugherty, A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice. Arterioscler. Thromb. Vasc. Biol., 2002, 22(3), 456-461.
183. Yao, L.; Huang, K.; Huang, D.; Wang, J.; Guo, H.; Liao, Y. Acute myocardial infarction induced increases in plasma tumor necrosis factor-alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell. Int. J. Cardiol., 2008, 123(3), 366-368.
184. Kim, Y.K.; Jung, H.G.; Myint, A.M.; Kim, H.; Park, S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord., 2007, 104(1-3), 91-95.
185. Profumo, E.; Buttari, B.; Tosti, M.E.; Siracusano, A.; Ortona, E.; Margutti, P.; Capoano, R.; Salvati, B.; Rigano, R. Association of intracellular pro-and anti-inflammatory cytokines in peripheral blood with the clinical or ultrasound indications for carotid en-darterectomy in patients with carotid atherosclerosis. Clin. Exp. Immunol., 2008, 152(1), 120-126.
186. Speiran, K.; Bailey, D.P.; Fernando, J.; Macey, M.; Barnstein, B.; Kolawole, M.; Curley, D.; Watowich, S.S.; Murray, P.J.; Oskeritz-ian, C.; Ryan, J.J. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J. Leukoc. Biol., 2009, 85(5), 826-836.
187. Sasaguri, T.; Arima, N.; Tanimoto, A.; Shimajiri, S.; Hamada, T.; Sasaguri, Y. A role for interleukin 4 in production of matrix metal-loproteinase 1 by human aortic smooth muscle cells. Atherosclerosis, 1998, 138(2), 247-253.
188. George, J.; Shoenfeld, Y.; Gilburd, B.; Afek, A.; Shaish, A.; Harats, D. Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ. Res., 2000, 86(12), 1203-1210.
189. MacLauchlan, S.; Skokos, E.A.; Meznarich, N.; Zhu, D.H.; Raoof, S.; Shipley, J.M.; Senior, R.M.; Bornstein, P.; Kyriakides, T.R. Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. J. Leukoc. Biol., 2009, 85(4), 617-626.
190. Njoku, D.B.; Li, Z.; Washington, N.D.; Mellerson, J.L.; Talor, M.V.; Sharma, R.; Rose, N.R. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury. Eur. J. Immunol., 2009, 39(6), 1652-1663.
191. Zubiaga, A.M.; Munoz, E.; Huber, B. T. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J. Immunol., 1992, 149(1), 107-112.
192. Burgis, S.; Gessner, A. Unexpected phenotype of STAT6 heterozygous mice implies distinct STAT6 dosage requirements for different IL-4 functions. Int. Arch. Allergy Immunol., 2007, 143(4), 263-268.
193. King, V.L.; Cassis, L.A.; Daugherty, A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am. J. Pathol., 2007, 171(6), 2040-2047.
194. Hong, H.Y.; Lee, H.Y.; Kwak, W.; Yoo, J.; Na, M.H.; So, I.S.; Kwon, T.H.; Park, H.S.; Huh, S.; Oh, G.T.; Kwon, I.C.; Kim, I.S.; Lee, B.H. Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis. J. Cell. Mol. Med., 2008, 12(5B), 2003-2014.
195. Das, J.; Chen, C.H.; Yang, L.; Cohn, L.; Ray, P.; Ray, A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol., 2001, 2(1), 45-50.
196. Cannons, J.L.; Yu, L.J.; Hill, B.; Mijares, L.A.; Dombroski, D.; Nichols, K.E.; Antonellis, A.; Koretzky, G.A.; Gardner, K.; Schwartzberg, P.L. SAP regulates T(H)2 differentiation and PKC-theta-mediated activation of NF-kappaB1. Immunity, 2004, 21(5), 693-706.
197. Hofer, T.; Nathansen, H.; Lohning, M.; Radbruch, A.; Heinrich, R. GATA-3 transcriptional imprinting in Th2 lymphocytes: a mathematical model. Proc. Natl. Acad. Sci. USA, 2002, 99(14), 9364-9368.
198. Lopez-Franco, O.; Hernandez-Vargas, P.; Ortiz-Munoz, G.; San-juan, G.; Suzuki, Y.; Ortega, L.; Blanco, J.; Egido, J.; Gomez-Guerrero, C. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2006, 26(8), 1864-1870.
199. Takatsu, K. Interleukin 5 and B cell differentiation. Cytokine Growth Factor Rev., 1998, 9(1), 25-35.
200. Sampi, M.; Ukkola, O.; Paivansalo, M.; Kesaniemi, Y.A.; Binder, C.J.; Horkko, S. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J. Am. Coll. Cardiol., 2008, 52(17), 1370-1378.
201. Binder, C.J.; Hartvigsen, K.; Chang, M.K.; Miller, M.; Broide, D.; Palinski, W.; Curtiss, L.K.; Corr, M.; Witztum, J.L. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest., 2004, 114(3), 427-437.
202. Del Vecchio, G.C.; Martire, B.; Lassandro, G.; Cecinati, V.; De Mattia, D.; Ciccarelli, M.; Piacente, L.; Giordano, P. Reduced in-terleukin-5 production by peripheral CD4+ T cells in common variable immunodeficiency patients. Immunopharmacol. Immuno-toxicol., 2008, 30(4), 679-686.
203. Mallat, Z.; Taleb, S.; Ait-Oufella, H.; Tedgui, A. The role of adaptive T cell immunity in atherosclerosis. J. Lipid Res., 2009, (50 Suppl.), S364-S369.
204. Daugherty, A.; Rateri, D.L.; King, V.L. IL-5 links adaptive and natural immunity in reducing atherosclerotic disease. J. Clin. Invest., 2004, 114(3), 317-319.
205. Folco, E.J.; Rocha, V.Z.; Lopez-Ilasaca, M.; Libby, P. Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. J. Biol. Chem., 2009, 284(38), 25569-25575.
206. Han, X.; Kitamoto, S.; Wang, H.; Boisvert, W.A. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J., 2010, 24(8), 2869-2880.
207. Potteaux, S.; Esposito, B.; van Oostrom, O.; Brun, V.; Ardouin, P.; Groux, H.; Tedgui, A.; Mallat, Z. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol., 2004, 24(8), 1474-1478.
208. Namiki, M.; Kawashima, S.; Yamashita, T.; Ozaki, M.; Sakoda, T.; Inoue, N.; Hirata, K.; Morishita, R.; Kaneda, Y.; Yokoyama, M. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis, 2004, 172(1), 21-29.
209. Akdis, M.; Verhagen, J.; Taylor, A.; Karamloo, F.; Karagiannidis, C.; Crameri, R.; Thunberg, S.; Deniz, G.; Valenta, R.; Fiebig, H.; Kegel, C.; Disch, R.; Schmidt-Weber, C.B.; Blaser, K.; Akdis, C.A. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med., 2004, 199(11), 1567-1575.
210. Croons, V.; Martinet, W.; Herman, A.G.; Timmermans, J.P.; De Meyer, G.R. The protein synthesis inhibitor anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther., 2009, 329(3), 856-864.
211. Castelli, L.; Comi, C.; Chiocchetti, A.; Nicola, S.; Mesturini, R.; Giordano, M.; D'Alfonso, S.; Cerutti, E.; Galimberti, D.; Fenoglio, C.; Tesser, F.; Yagi, J.; Rojo, J.M.; Perla, F.; Leone, M.; Scarpini, E.; Monaco, F.; Dianzani, U. ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. J. Neuroimmunol., 2007, 186(1-2), 193-198.
212. Lohning, M.; Hutloff, A.; Kallinich, T.; Mages, H.W.; Bonhagen, K.; Radbruch, A.; Hamelmann, E.; Kroczek, R.A. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J. Exp. Med., 2003, 197(2), 181-193.
213. Witsch, E.J.; Peiser, M.; Hutloff, A.; Buchner, K.; Dorner, B.G.; Jonuleit, H.; Mages, H.W.; Kroczek, R.A. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur. J. Immunol., 2002, 32(9), 2680-2686.
214. Taylor, A.; Akdis, M.; Joss, A.; Akkoc, T.; Wenig, R.; Colonna, M.; Daigle, I.; Flory, E.; Blaser, K.; Akdis, C.A. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J. Allergy Clin. Immunol., 2007, 120(1), 76-83.
215. Caligiuri, G.; Rudling, M.; Ollivier, V.; Jacob, M.P.; Michel, J.B.; Hansson, G.K.; Nicoletti, A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med., 2003, 9(1-2), 10-17.
216. Fichtlscherer, S.; Breuer, S.; Heeschen, C.; Dimmeler, S.; Zeiher, A.M. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J. Am. Coll. Cardiol., 2004, 44(1), 44-49.
217. Goswami, B.; Rajappa, M.; Mallika, V.; Shukla, D.K.; Kumar, S. TNF-alpha/IL-10 ratio and C-reactive protein as markers of the inflammatory response in CAD-prone North Indian patients with acute myocardial infarction. Clin. Chim. Acta, 2009, 408(1-2), 14-18.
218. Von Der Thusen, J.H.; Kuiper, J.; Fekkes, M.L.; De Vos, P.; Van Berkel, T.J.; Biessen, E.A. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/-mice. FASEB J., 2001, 15(14), 2730-2732.
219. Pinderski, L.J.; Fischbein, M.P.; Subbanagounder, G.; Fishbein, M.C.; Kubo, N.; Cheroutre, H.; Curtiss, L.K.; Berliner, J.A.; Boisvert, W.A. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res., 2002, 90(10), 1064-1071.
220. McGuirk, P.; Mills, K.H. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol., 2002, 23(9), 450-455.
221. Liew, F.Y.; Pitman, N.I.; McInnes, I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol., 2010, 10(2), 103-110.
222. Miller, A.M.; Xu, D.; Asquith, D.L.; Denby, L.; Li, Y.; Sattar, N.; Baker, A.H.; McInnes, I.B.; Liew, F.Y. IL-33 reduces the development of atherosclerosis. J. Exp. Med., 2008, 205(2), 339-346.
223. Schmitz, J.; Owyang, A.; Oldham, E.; Song, Y.; Murphy, E.; McClanahan, T.K.; Zurawski, G.; Moshrefi, M.; Qin, J.; Li, X.; Gorman, D.M.; Bazan, J.F.; Kastelein, R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005, 23(5), 479-490.
224. Hayakawa, H.; Hayakawa, M.; Kume, A.; Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem., 2007, 282(36), 26369-26380.
225. Hamann, D.; Hilkens, C.M.; Grogan, J.L.; Lens, S.M.; Kapsenberg, M.L.; Yazdanbakhsh, M.; van Lier, R. A. CD30 expression does not discriminate between human Th1-and Th2-type T cells. J. Immunol., 1996, 156(4), 1387-1391.
226. Maecker, H.T.; Do, M.S.; Levy, S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc. Natl. Acad. Sci. USA, 1998, 95(5), 2458-2462.
227. Maecker, H.T. Human CD81 directly enhances Th1 and Th2 cell activation, but preferentially induces proliferation of Th2 cells upon long-term stimulation. BMC Immunol., 2003, 4, 1.
228. Weng, A.P.; Shahsafaei, A.; Dorfman, D.M. CXCR4/CD184 im-munoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1-Th2+ immunophenotype. Am. J. Clin. Pathol., 2003, 119(3), 424-430.
229. Sen, Y.; Chunsong, H.; Baojun, H.; Linjie, Z.; Qun, L.; San, J.; Qiuping, Z.; Junyan, L.; Zhang, X.; Jinquan, T. Aberration of CCR7 CD8 memory T cells from patients with systemic lupus erythematosus: an inducer of T helper type 2 bias of CD4 T cells. Immunology, 2004, 112(2), 274-289.
230. Soler, D.; Chapman, T. R.; Poisson, L.R.; Wang, L.; Cote-Sierra, J.; Ryan, M.; McDonald, A.; Badola, S.; Fedyk, E.; Coyle, A.J.; Hodge, M.R.; Kolbeck, R. CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J. Immunol., 2006, 177(10), 6940-6951.
231. Hutloff, A.; Dittrich, A.M.; Beier, K.C.; Eljaschewitsch, B.; Kraft, R.; Anagnostopoulos, I.; Kroczek, R.A. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature, 1999, 397(6716), 263-366.
232. Rojo, J.M.; Pini, E.; Ojeda, G.; Bello, R.; Dong, C.; Flavell, R.A.; Dianzani, U.; Portoles, P. CD4+ICOS+ T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'. Int. Immunol., 2008, 20(4), 577-589.
233. Caruso, R.; Stolfi, C.; Sarra, M.; Rizzo, A.; Fantini, M.C.; Pallone, F.; MacDonald, T.T.; Monteleone, G. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood, 2009, 113(15), 3512-3519.
234. Swaidani, S.; Bulek, K.; Kang, Z.; Liu, C.; Lu, Y.; Yin, W.; Aronica, M.; Li, X. The critical role of epithelial-derived Act1 in IL-17-and IL-25-mediated pulmonary inflammation. J. Immunol., 2009, 182(3), 1631-1640.
235. Perrigoue, J.G.; Zaph, C.; Guild, K.; Du, Y.; Artis, D. IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection. J. Immunol., 2009, 182(10), 6088-6094.
236. Khademi, M.; Illes, Z.; Gielen, A.W.; Marta, M.; Takazawa, N.; Baecher-Allan, C.; Brundin, L.; Hannerz, J.; Martin, C.; Harris, R.A.; Hafler, D.A.; Kuchroo, V.K.; Olsson, T.; Piehl, F.; Wall-strom, E. T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononu-clear cells in multiple sclerosis. J. Immunol., 2004, 172(11), 7169-7176.
237. Shevach, E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity, 2006, 25(2), 195-201.
238. Cottrez, F.; Groux, H. Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation, 2004, 77(1 Suppl.), S12-S15.
239. George, J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. Nat. Clin. Pract. Cardiovasc. Med., 2008,5(9), 531-540.
240. Ait-Oufella, H.; Salomon, B.L.; Potteaux, S.; Robertson, A.K.; Gourdy, P.; Zoll, J.; Merval, R.; Esposito, B.; Cohen, J.L.; Fisson, S.; Flavell, R.; Hansson, G.K.; Klatzmann, D.; Tedgui, A.; Mallat, Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med., 2006, 12(2), 178-180.
241. Shi, F.D.; Li, H.; Wang, H.; Bai, X.; van der Meide, P.H.; Link, H.; Ljunggren, H.G. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J. Immunol., 1999, 162(10), 5757-5763.
242. Riley, J.L.; June, C.H.; Blazar, B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity, 2009, 30(5), 656-665.
243. Weiner, H.L. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect., 2001, 3(11), 947-954.
244. Villares, R.; Cadenas, V.; Lozano, M.; Almonacid, L.; Zaballos, A.; Martinez-A, C.; Varona, R. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur. J. Immunol., 2009, 39(6), 1671-1681.
245. Lee, Y.K.; Turner, H.; Maynard, C.L.; Oliver, J.R.; Chen, D.; El-son, C.O.; Weaver, C.T. Late developmental plasticity in the T helper 17 lineage. Immunity, 2009, 30(1), 92-107.
246. Faria, A.M.; Weiner, H.L. Oral tolerance. Immunol. Rev., 2005, 206, 232-259.
247. McCaffrey, T.A.; Du, B.; Consigli, S.; Szabo, P.; Bray, P.J.; Hart-ner, L.; Weksler, B.B.; Sanborn, T.A.; Bergman, G.; Bush, H.L.Jr. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J. Clin. Invest., 1997, 100(9), 2182-2188.
248. Kulkarni, A.B.; Huh, C.G.; Becker, D.; Geiser, A.; Lyght, M.; Flanders, K.C.; Roberts, A.B.; Sporn, M.B.; Ward, J.M.; Karlsson, S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA, 1993, 90(2), 770-774.
249. Fukaura, H.; Kent, S.C.; Pietrusewicz, M.J.; Khoury, S.J.; Weiner, H.L.; Hafler, D.A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest., 1996, 98(1), 70-77.
250. Thomas, D.A.; Massague, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell., 2005, 8(5), 369-380.
251. Mallat, Z.; Besnard, S.; Duriez, M.; Deleuze, V.; Emmanuel, F.; Bureau, M.F.; Soubrier, F.; Esposito, B.; Duez, H.; Fievet, C.; Staels, B.; Duverger, N.; Scherman, D.; Tedgui, A. Protective role of interleukin-10 in atherosclerosis. Circ. Res., 1999, 85(8), e17-e24.
252. Lutgens, E.; Gijbels, M.; Smook, M.; Heeringa, P.; Gotwals, P.; Koteliansky, V.E.; Daemen, M.J. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol., 2002, 22(6), 975-982.
253. Robertson, A.K.; Rudling, M.; Zhou, X.; Gorelik, L.; Flavell, R.A.; Hansson, G.K. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest., 2003, 112(9), 1342-1350.
254. Carrier, Y.; Yuan, J.; Kuchroo, V.K.; Weiner, H.L. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J. Immunol., 2007, 178(1), 172-178.
255. Zhou, X.; Johnston, T.P.; Johansson, D.; Parini, P.; Funa, K.; Svensson, J.; Hansson, G.K. Hypercholesterolemia leads to elevated TGF-beta1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice. Atherosclerosis, 2009, 204(2), 381-387.
256. Samarakoon, R.; Higgins, P.J. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb. Haemost., 2008, 100(6), 976-983.
257. Park, H.; Li, Z.; Yang, X.O.; Chang, S.H.; Nurieva, R.; Wang, Y.H.; Wang, Y.; Hood, L.; Zhu, Z.; Tian, Q.; Dong, C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol., 2005, 6(11), 1133-1141.
258. McGeachy, M.J.; Cua, D.J. Th17 cell differentiation: the long and winding road. Immunity, 2008, 28(4), 445-53.
259. Mangan, P.R.; Harrington, L.E.; O'Quinn, D.B.; Helms, W.S.; Bullard, D.C.; Elson, C.O.; Hatton, R.D.; Wahl, S.M.; Schoeb, T.R.; Weaver, C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature, 2006, 441(7090), 231-234.
260. Veldhoen, M.; Hocking, R.J.; Atkins, C.J.; Locksley, R.M.; Stock-inger, B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 2006, 24(2), 179-189.
261. Yang, L.; Anderson, D.E.; Baecher-Allan, C.; Hastings, W.D.; Bettelli, E.; Oukka, M.; Kuchroo, V.K.; Hafler, D.A. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature, 2008, 454(7202), 350-352.
262. Manel, N.; Unutmaz, D.; Littman, D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol., 2008, 9(6), 641-649.
263. Volpe, E.; Servant, N.; Zollinger, R.; Bogiatzi, S.I.; Hupe, P.; Bar-illot, E.; Soumelis, V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol., 2008, 9(6), 650-657.
264. Knippertz, I.; Hesse, A.; Schunder, T.; Kampgen, E.; Brenner, M.K.; Schuler, G.; Steinkasserer, A.; Nettelbeck, D.M. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J. Immunother., 2009, 32(5), 524-538.
265. Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med., 2007, 13(2), 139-145.
266. Dong, C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol., 2008, 8(5), 337-348.
267. Eid, R.E.; Rao, D.A.; Zhou, J.; Lo, S.F.; Ranjbaran, H.; Gallo, A.; Sokol, S.I.; Pfau, S.; Pober, J.S.; Tellides, G. Interleukin-17 and in-terferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation, 2009, 119(10), 1424-1432.
268. Sutton, C.; Brereton, C.; Keogh, B.; Mills, K.H.; Lavelle, E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med., 2006, 203(7), 1685-1691.
269. Yu, J.J.; Gaffen, S.L. Interleukin-17: a novel inflammatory cyto-kine that bridges innate and adaptive immunity. Front. Biosci., 2008, 13, 170-177.
270. Miyahara, Y.; Odunsi, K.; Chen, W.; Peng, G.; Matsuzaki, J.; Wang, R. F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. USA, 2008, 105(40), 15505-15510.
271. Morishima, N.; Mizoguchi, I.; Takeda, K.; Mizuguchi, J.; Yoshi-moto, T. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem. Biophys. Res. Com-mun., 2009, 386(1), 105-110.
272. Kondo, T.; Takata, H.; Matsuki, F.; Takiguchi, M. Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J. Immunol., 2009, 182(4), 1794-1798.
273. Pejnovic, N.; Vratimos, A.; Lee, S.H.; Popadic, D.; Takeda, K.; Akira, S.; Chan, W.L. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat die. Mol. Immunol., 2009, 47(1), 37-45.
274. Yoshimura, T.; Sonoda, K. H.; Ohguro, N.; Ohsugi, Y.; Ishibashi, T.; Cua, D.J.; Kobayashi, T.; Yoshida, H.; Yoshimura, A. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford), 2009, 48(4), 347-354.
275. Rouvier, E.; Luciani, M.F.; Mattei, M.G.; Denizot, F.; Golstein, P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol., 1993, 150(12), 5445-5456.
276. van Hamburg, J.P.; Asmawidjaja, P.S.; Davelaar, N.; Mus, A.M.; Colin, E.M.; Hazes, J.M.; Dolhain, R.J.; Lubberts, E. Th17 but not Th1 cells from early RA patients are potent inducers of MMPs and IL-6, IL-8 upon RASF interaction including autocrine IL-17A production. Arthritis Rheum., 2010, Oct 15. [Epub ahead of print]
277. Chen, S.; Shimada, K.; Zhang, W.; Huang, G.; Crother, T.R.; Arditi, M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J. Immunol., 2010, 185(9), 5619-5627.
278. Bouguermouh, S.; Fortin, G.; Baba, N.; Rubio, M.; Sarfati, M. CD28 co-stimulation down regulates Th17 development. PLoS One, 2009, 4(3), e5087.
279. Ichiyama, K.; Hashimoto, M.; Sekiya, T.; Nakagawa, R.; Wakabayashi, Y.; Sugiyama, Y.; Komai, K.; Saba, I.; Möröy, T.; Yoshimura, A. Gfi1 negatively regulates T(h)17 differentiation by inhibiting RORgammat activity. Int. Immunol., 2009, 21(7), 881-889.
280. Korn, T.; Mitsdoerffer, M.; Croxford, A.L.; Awasthi, A.; Dardal-hon, V.A.; Galileos, G.; Vollmar, P.; Stritesky, G.L.; Kaplan, M.H.; Waisman, A.; Kuchroo, V.K.; Oukka, M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA, 2008, 105(47), 18460-18465.
281. Ramgolam, V.S.; Sha, Y.; Jin, J.; Zhang, X.; Markovic-Plese, S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol., 2009,183(8), 5418-5427.
282. Wolk, K.; Witte, E.; Witte, K.; Warszawska, K.; Sabat, R. Biology of interleukin-22. Semin. Immunopathol., 2010, 32(1), 17-31.
283. Teng, M.W.; Andrews, D.M.; McLaughlin, N.; von Scheidt, B.; Ngiow, S.F.; Moller, A.; Hill, G.R.; Iwakura, Y.; Oft, M.; Smyth, M. J. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc. Natl. Acad. Sci. USA, 2010, 107(18), 8328-8333.
284. Xiao, S.; Jin, H.; Korn, T.; Liu, S.M.; Oukka, M.; Lim, B.; Kuchroo, V.K. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol., 2008, 181(4), 2277-2284.
285. El-behi, M.; Ciric, B.; Yu, S.; Zhang, G.X.; Fitzgerald, D. C.; Ro-stami, A. Differential effect of IL-27 on developing versus committed Th17 cells. J. Immunol., 2009, 183(8), 4957-4967.
286. Passos, S.T.; Silver, J.S.; O'Hara, A.C.; Sehy, D.; Stumhofer, J.S.; Hunter, C.A. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol., 2010, 184(4), 1776-1783.
287. Baba, N.; Rubio, M.; Sarfati, M. Interplay between CD45RA+ regulatory T cells and TNF-alpha in the regulation of human Th17 differentiation. Int. Immunol., 2010, 22(4), 237-244.
288. Tellides, G.; Tereb, D.A.; Kirkiles-Smith, N.C.; Kim, R.W.; Wilson, J.H.; Schechner, J.S.; Lorber, M.I.; Pober, J.S. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature, 2000, 403(6766), 207-211.